Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators
dc.authorid | Cakir, Erkan/0000-0002-1438-7854 | |
dc.authorid | Nayir Buyuksahin, Halime/0000-0002-6909-7993 | |
dc.authorid | Arik, Elif/0000-0002-7319-8535 | |
dc.authorid | Serbes, Mahir/0000-0001-6422-2639 | |
dc.authorid | Kartal Ozturk, Gokcen/0000-0002-0793-9710 | |
dc.authorid | karcioglu, oguz/0000-0002-6071-0851 | |
dc.contributor.author | Buyuksahin, Halime Nayir | |
dc.contributor.author | Emiralioglu, Nagehan | |
dc.contributor.author | Yalcin, Ebru | |
dc.contributor.author | Sen, Velat | |
dc.contributor.author | Sen, Hadice Selimoglu | |
dc.contributor.author | Arslan, Huseyin | |
dc.contributor.author | Baskan, Azer Kilic | |
dc.date.accessioned | 2025-02-22T14:09:09Z | |
dc.date.available | 2025-02-22T14:09:09Z | |
dc.date.issued | 2024 | |
dc.department | Dicle Üniversitesi | en_US |
dc.description.abstract | Introduction: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs target the underlying defect and improve CFTR function. They are a part of standard care in many countries, but not all patients are eligible for these drugs due to age and genotype. Here, we aimed to determine the characteristics of non-eligible patients for CFTR modulators in the CF registry of Turkey (CFRT) to highlight their clinical needs. Methods: This retrospective cohort study included CF patient data from the CFRT in 2021. The decision of eligibility for the CFTR modulator was determined according to the 'Vertex treatment-Finder' on the Vertex (R) website. Demographic and clinical characteristics of patients were compared between eligible (group 1) and ineligible (group 2) groups for CFTR modulators. Results: Among the study population (N = 1527), 873 (57.2%) were in group 1 and 654 (42.8%) were in group 2. There was no statistical difference between groups regarding sex, meconium ileus history, diagnoses via newborn screening, FEV1 z-score, CF-associated complications, organ transplant history, and death. Patients in group 2 had a higher incidence of pancreatic insufficiency (87.7% vs. 83.2%, p = .010), lower median height z-scores (-0.87 vs. -0.55, p < .001), lower median body mass index z-scores (-0.65 vs. -0.50, p < .001), longer days receiving antibiotics due to pulmonary exacerbation (0 [interquartile range, IQR: 0-2] vs. 0 [IQR: 0-7], p = 0.001), and more non-invasive ventilation support (2.6% vs. 0.9%, p = 0.008) than patients in group 1. Conclusion: The ineligible group had worse clinical outcomes than the eligible group. This highlights their need for life-changing drugs to improve clinical outcomes. | en_US |
dc.description.sponsorship | None | en_US |
dc.description.sponsorship | We would like to thank the Cystic Fibrosis Registry of Turkey for supplying access to patient data and individual center representatives for allowing the use of their data. | en_US |
dc.identifier.doi | 10.1002/ppul.27051 | |
dc.identifier.endpage | 2506 | en_US |
dc.identifier.issn | 8755-6863 | |
dc.identifier.issn | 1099-0496 | |
dc.identifier.issue | 10 | en_US |
dc.identifier.pmid | 38771207 | en_US |
dc.identifier.scopus | 2-s2.0-85193687493 | en_US |
dc.identifier.scopusquality | Q1 | en_US |
dc.identifier.startpage | 2499 | en_US |
dc.identifier.uri | https://doi.org/10.1002/ppul.27051 | |
dc.identifier.uri | https://hdl.handle.net/11468/29813 | |
dc.identifier.volume | 59 | en_US |
dc.identifier.wos | WOS:001228233000001 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | |
dc.indekslendigikaynak | Scopus | |
dc.indekslendigikaynak | PubMed | |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.ispartof | Pediatric Pulmonology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.snmz | KA_WOS_20250222 | |
dc.subject | CFTR modulators | en_US |
dc.subject | clinical features | en_US |
dc.subject | cystic fibrosis | en_US |
dc.subject | eligibility | en_US |
dc.subject | registry | en_US |
dc.title | Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators | en_US |
dc.type | Article | en_US |